Zobrazeno 1 - 10
of 113
pro vyhledávání: '"F.M. Perrotta"'
Publikováno v:
Reumatismo, Vol 72, Iss 3 (2020)
In this manuscript we aim to describe a particular case of a 63 years-old man who developed three different malignancies (one was a rare case of breast cancer) among nearly five years. In particular, for the diagnosis of melanoma, he was treated with
Externí odkaz:
https://doaj.org/article/ded68aa061c44417825e5926d6a831f0
Autor:
F.M. Perrotta, A. Delle Sedie, S. Scriffignano, P. Volpe, E. Cordisco, N. Milano, M. Gabini, E. Lubrano
Publikováno v:
Reumatismo, Vol 72, Iss 1 (2020)
The development of new biologic and targeted synthetic DMARDs can lead to good disease control. The aim of the present study was to assess the rate of remission and low disease activity, and the improvement of pain and function, in psoriatic arthriti
Externí odkaz:
https://doaj.org/article/e8f2510c6da64cdc9896d162303aa8ea
Publikováno v:
Reumatismo, Vol 69, Iss 1, Pp 1-8 (2017)
Spondyloarthritis (SpAs) are a group of chronic inflammatory diseases that affect joints and enthesis with a possible involvement of other districts such as skin, eye and bowel. In SpAs, the inflammatory process could lead to both erosive damage (as
Externí odkaz:
https://doaj.org/article/d1baa81489184239b7ca7f72d6460ff8
Publikováno v:
Reumatismo, Vol 71, Iss 2 (2019)
We present the case of a patient with psoriatic arthritis (PsA) mutilans and occult axial involvement. The patient had suffered from PsA mutilans for more than a decade, with severe residual articular damage, but had been in clinical remission for ye
Externí odkaz:
https://doaj.org/article/266bf0ad054549e390485592892d80bb
Autor:
F.M. Perrotta, E. Lubrano
Publikováno v:
Reumatismo, Vol 68, Iss 2, Pp 57-64 (2016)
Psoriatic arthritis (PsA) is a chronic inflammatory disease that possibly leads to structural damage and to a reduction of joint function and poor quality of life. Treatment of PsA has changed since its introduction of anti- TNF drugs, which have sho
Externí odkaz:
https://doaj.org/article/a669a11025874fff97174e73690ac091
Autor:
F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro
Publikováno v:
Reumatismo, Vol 66, Iss 3, Pp 208-214 (2014)
The objective of this study was to evaluate the predictive factors for achieving partial remission (PR) in patients with ankylosing spondylitis (AS) treated with anti-TNFα. We longitudinally enrolled in a multi-center study 214 AS patients, classifi
Externí odkaz:
https://doaj.org/article/52e8357f4b0f46e09f8a995067387fa5
Publikováno v:
Reumatismo, Vol 65, Iss 3, Pp 105-112 (2013)
The aim of the study was to evaluate atherosclerosis in ankylosing spondylitis (AS) through the assessment of morphological and functional measures of subclinical atherosclerosis. Twenty patients [M/F=12/8, age (median/range) 43.5/28-69 years; diseas
Externí odkaz:
https://doaj.org/article/1f478481c66c460fb9c9e60289524ea7
Publikováno v:
Reumatismo, Vol 65, Iss 3, Pp 134-137 (2013)
In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resona
Externí odkaz:
https://doaj.org/article/d398f1c0e2574c5e91fda21da93fe6eb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.